Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004929 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00004929: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004929 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004929, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
Interventions
- BIOLOGICAL QS21
- BIOLOGICAL MUC-2-KLH vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1999-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004929
The ClinicalTrials.gov registry entry for NCT00004929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QS21 is the first listed.
NCT00004929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004929 about?
NCT00004929 is a clinical study titled "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
What is the current status of trial NCT00004929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1999-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00004929?
The interventions under investigation include: QS21 (BIOLOGICAL), MUC-2-KLH vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004929?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.